Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

Core Viewpoint - Cytek Biosciences, Inc. anticipates a total revenue of approximately $201 million for the full year 2025, with fourth-quarter revenue expected to be around $62 million, indicating growth compared to previous periods [2][3]. Financial Performance - The expected revenue for the fourth quarter of 2025 represents an 8% increase compared to the fourth quarter of 2024 and a 19% increase compared to the third quarter of 2025 [2]. - The fourth quarter revenue growth reflects a meaningful acceleration compared to earlier quarters in 2025, driven by strong growth in Services, Reagents, and instrument revenue in the Asia Pacific region, as well as improvements in the US and EMEA markets [3]. Company Presentation - Cytek will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 PM Pacific Time, with live and archived webcasts available on the company's website [4]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5]. - The company's product offerings include various flow cytometers, imaging products, reagents, and software, aimed at providing a comprehensive suite of solutions for customers [5].